A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-394
- Sponsors Merck Sharp & Dohme
- 15 Nov 2018 Planned number of patients changed from 330 to 450.
- 15 Nov 2018 Planned End Date changed from 27 Apr 2021 to 4 Jan 2022.
- 12 Jun 2018 Planned End Date changed from 23 Dec 2019 to 27 Apr 2021.